YDO1 Stock Overview
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for YDO1 from our risk checks.
Madrigal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$190.35 |
| 52 Week High | US$295.00 |
| 52 Week Low | US$112.60 |
| Beta | -0.44 |
| 1 Month Change | -16.22% |
| 3 Month Change | -7.87% |
| 1 Year Change | -30.93% |
| 3 Year Change | 71.49% |
| 5 Year Change | 105.47% |
| Change since IPO | 72,831.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| YDO1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.6% | -1.2% | 1.7% |
| 1Y | -30.9% | -23.0% | 2.3% |
Price Volatility
| YDO1 volatility | |
|---|---|
| YDO1 Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 376 | Bill Sibold | www.madrigalpharma.com |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. Fundamentals Summary
| YDO1 fundamental statistics | |
|---|---|
| Market cap | €4.01b |
| Earnings (TTM) | - €348.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.5x
P/E RatioIs YDO1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YDO1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$373.63m |
| Earnings | -US$373.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -17.80 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 28.5% |
How did YDO1 perform over the long term?
See historical performance and comparison